Additional Proxy Soliciting Materials (definitive) (defa14a)
September 18 2020 - 5:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☒
|
Definitive Additional Materials
|
|
☐
|
Soliciting
Material Pursuant to Rule 14a-11(c) or rule 14a-12
|
OPGEN, INC.
(Name
of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement,
if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
☐
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11:
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
☐
|
Fee paid previously with preliminary materials:
|
|
☐
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule
and the date of its filing.
|
|
(1)
|
Amount previously paid:
|
|
(2)
|
Form, Schedule or Registration Statement no.:
|
The following press release was issued
by OpGen, Inc. on September 18, 2020.
|
|
OpGen,
Inc. Announces Notice of Annual Meeting Venue Change
GAITHERSBURG,
MD.—September 18, 2020--OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”) announced today that
it has changed the venue of its 2020 Annual Meeting of Stockholders due to continuing health and safety considerations arising
from the COVID-19 pandemic. As a result, the Company’s 2020 Annual Meeting of Stockholders will now be held at OpGen’s
corporate headquarters at 708 Quince Orchard Road, Gaithersburg, Maryland 20878.
The
Company’s 2020 Annual Meeting of Stockholders will be held, as scheduled, on Wednesday, September 30, 2020 at 10 a.m.
ET. As noted in the proxy statement filed by the Company on August 20, 2020, stockholders of record as of end of business on
August 17, 2020 may continue to vote at http://www.pstvote.com/opgen2020, by phone, and by mail until 11:59 p.m. ET on
September 29, 2020, in accordance with the instructions provided in the proxy materials.
For
stockholders who intend to attend the 2020 Annual Meeting of Stockholders in person and are legally permitted to do so, the Company
respectfully requests that they contact the Company’s corporate offices at (240) 813-1260 no later than 5 p.m. ET on Monday,
September 28, 2020 so that the Company can be appropriately prepared. The Company advises that stockholders who are experiencing
any potential COVID-19 symptoms or who have been in contact with any person experiencing any potential COVID-19 symptoms should
not attend the annual meeting in person. The Company may put in place additional procedures or limitations on meeting attendees,
including limiting seating, requiring health screenings, protective masks and other reasonable or required measures in order to
enter the meeting location.
For
further information, please refer to the Company’s Notice of 2020 Annual Meeting of Stockholders and Proxy Statement, filed
with the Securities and Exchange Commission on August 20, 2020, which can be accessed at http://ir.opgen.com/sec-filings.
About
OpGen, Inc.
OpGen,
Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics
to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing
molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening
infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or
MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology
Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.
For
more information, please visit www.opgen.com.
Forward-Looking
Statements by OpGen
This
press release includes statements regarding the OpGen’s 2020 Annual Meeting of Stockholders. These statements constitute
"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are
beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to
differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively
develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of
our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the impact
of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets
and general economic conditions, the realization of expected benefits of our business combination transaction with Curetis GmbH,
the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion
of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities
and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on
our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation
to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen
Contact:
Oliver
Schacht
CEO
InvestorRelations@opgen.com
Press
Contact:
Matthew
Bretzius
FischTank
Marketing and PR
matt@fischtankpr.com
Investor
Contact:
Megan
Paul
Edison
Group
mpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024